Retatrutide Costs $0.78/mg at the Source. Resellers Charge You 3x to 22x for the Same Vial.

Here is the trade that runs the entire US research-peptide market. A factory in China makes the powder. An American "vendor" buys it in bulk, repackages it under a brand with a metallic label and an "-alpha" or "-labs" suffix, and ships it from a domestic warehouse at three to twenty-two times what it paid. Most buyers never learn the source exists. This piece is not an argument against grey-market sourcing, which is a real and legal-adjacent way for people to reach compounds the regulated system gates off. It is an argument against the two things the markup hides: the source price, and the lab test.

The number that starts the argument

Retatrutide is the most-wanted compound in this market right now, so start there. Pull every in-stock vendor row, compute the price per milligram as cost divided by total milligrams in the vial, drop the blends, and take the median. The answer is $0.7767 per mg, which rounds to the $0.78/mg figure the market has already confirmed elsewhere. That is 125 separate in-stock listings agreeing on a floor.

Now walk up the layers. The cheapest single US reseller DisclosedLabs can surface for retatrutide is $2.36/mg, which is their headline best-case number, the lowest reseller they found, not a median. That alone is 3.0x the source. The PeptideBase median across 26 vendors is $10.00/mg. That is 12.9x the source. The median buyer, the one who picks a normal reseller off a normal list, is paying roughly thirteen dollars for one dollar of compound.

The retatrutide row matters most because it is the one we can check hardest. Our median reproduced the independently confirmed $0.78/mg to the cent, which means the same method applied to the other five compounds is standing on validated ground.

The markup table: six compounds, one pattern

Same method across all six. “Source $/mg” is our in-stock vendor median, single-compound rows only, all blends excluded (Wolverine, GLOW, KLOW, Cagri-plus-Sema, anything-plus-TB-500), and Semax explicitly held out of the semaglutide match because it is a different molecule. “DisclosedLabs $/mg” is their cheapest-reseller headline, so the DL multiple is conservative by construction: it compares the best US reseller against our median. “PeptideBase $/mg” is a true cross-vendor median, so that multiple is median against median.

Read the spread, not just the headline. Tirzepatide is the widest grey-versus-reseller gap on the board: $0.40/mg at the source against an $8.90 median, 22.3x. GHK-Cu is the tightest against the cheapest reseller, where one US storefront sits at $0.093/mg, a hair above the $0.07 source floor, a 1.3x gap, yet the same compound carries a $1.29 vendor median, which is 18.4x. Same molecule, two storefronts, an 18-fold spread between them. The reseller market is not pricing the peptide. It is pricing how much it thinks you will not check.

The supply chain: one source, many labels

The markup only makes sense once you see how thin the “vendor” actually is. Three facts set the floor.

First, the powder is almost all from one place. Roughly 99% of research peptides sold online are synthesized in China, including product marketed under American, European, and boutique brand names. The US “vendor” is usually not a manufacturer. It is an importer that repackages bulk lyophilized vials under a domestic brand and ships them from a domestic warehouse.

Second, the source is reachable by ordinary buyers. The factories market on RedNote, Instagram, and TikTok, then move the transaction to WhatsApp or Telegram the moment you ask for a price list. Forums like MESO-Rx host factory reps selling “China factory direct, Janoshik tested, worldwide shipping.” A WhatsApp-or-Telegram-only contact is itself the recognized industry tell for a source sitting one layer below the storefront you bought from.

Third, this is now a measurable trade lane, not a fringe. US customs data shows imports of hormone and peptide compounds from China roughly doubled to $328M in the first three quarters of 2025, up from $164M a year earlier.

The branding playbook: it is a kit, not a lab

The reason the markup buys so little is that the relabel step adds almost nothing to what is in the vial. White-label and dropship services turn “start a peptide brand” into a checkout flow: no upfront cost, no inventory, no touching the product. The fulfiller picks, packs, labels, and ships directly to the reseller’s customer under the reseller’s brand. The reseller’s only real assets are a name and a website.

The visual grammar is built to read as rigor. A holographic or metallic label to hint at the science. An “-alpha,” “-labs,” “-research,” or “-bio” suffix on the brand. An AI-generated logo and a clean storefront. None of these touch the molecule. They signal lab-grade discipline that the repackaging never added. The “for research use only, not for human consumption” line is part of the same costume: it is the legal posture that lets the product ship without manufacturing oversight, while the vial sizing and dosing clearly anticipate human use.

What the markup fairly buys, and what it does not

This is where the honest accounting lives, because the markup is not pure extraction. Some of it is real service.

The documented tier structure: a Chinese manufacturer sells at roughly $5 to $15 a vial in bulk; a US or EU reseller sells the same compound at roughly $35 to $75. Factory-direct sellers describe their own pricing as 50% to 90% below traditional resellers, and a 90% discount is a 10x markup read from the other end. A concrete worked example floating around the trade: tirzepatide at about $48 for ten 5mg vials direct, against the FDA-approved branded equivalent near $399 a month.

What the spread legitimately pays for: two-day domestic shipping instead of three weeks, no customs-seizure risk, smaller split quantities, an address you can complain to, and, for the honest vendors, a batch they actually paid Janoshik or Finnrick to test. That convenience-and-verification premium is defensible. A buyer who wants fast, clean, tested, and accountable is buying something real.

The part that does not survive transparency is the opacity premium: charging 10x while concealing that the upstream price is public and, often, that the upstream lab report is the same one. The honest test for any vendor is one question. Does the markup fund verification and service you can confirm, or just a sticker and a storefront theme?

The aggregators: cannot find the source, or will not show it?

A whole category of sites pitches itself as the fix: “we scrape the grey market so you see the real, lowest price.” Look at what they actually index. It is the layer of American resellers who buy off the same lines and resell at a markup. The real source sits one hop deeper, in Telegram channels and forum DMs, and it is not in their results. So their “lowest price” is the lowest price among middlemen. A discount off retail, not the source price.

That sets up a genuine question, and we pose it as a question on purpose. If your entire product is finding the lowest grey-market price, and the source is sitting one Telegram channel deeper, there are only two ways to explain why it never appears in your index.

We are not asserting which one it is. We are pointing out that both answers disqualify a thing that calls itself price transparency. Pick one.

There is an irony worth sitting with too. A site whose whole value proposition is scraping other people’s prices tends to block automated access the moment you try to scrape it. Transparency for thee. And if an aggregator publishes a single-unit listing it knows is roughly ten times the market rate as if it were a comparable data point, that is the tell: it is not a price-transparency tool, it is a price-noise aggregator.

What the buyer is, and is not, getting

Frequently the buyer is getting the identical vial from the identical factory line, and sometimes the identical third-party COA. Chinese suppliers send samples to Janoshik, the most-recognized independent peptide lab, and resellers forward those same reports. The COA is also the most-abused trust signal in the market. Two failure modes are well documented: a legitimate report from one batch reused to sell a different batch, and anonymously commissioned tests with no verifiable report ID. A COA proves a sample was tested. It does not prove your vial is that sample.

And the genuine downside risk is real, which is the other half of why a price-only view is dangerous. When a reseller skips verification, buys from the cheapest source, and generates a COA from manufacturer claims rather than independent testing, a meaningful share of the cheapest vials test below 85% purity, some at 60% to 70% of label. Paying more buys nothing if the markup did not fund a test, and paying less can mean the real per-mg cost is worse than the sticker because a third of the milligrams are not there. We took that dose-accuracy gap apart in the grey-market dose-accuracy analysis, which is the companion to this piece: price tells you the markup, the COA tells you whether the milligrams are real, and you need both numbers to know what you actually bought.

How to price a vial like the markup is not there

You do not need our data to do this. You need two numbers the storefront would rather you skip.

The first is the source price per milligram, which is the table above: divide a vendor’s price by the milligrams in the vial and compare it to the source floor for that compound. A $90 vial of 10mg retatrutide is $9.00/mg, which is 11.5x the $0.78 source. That is not a scam by itself, but it is a number you should see before you click, not after.

The second is the lab test for the actual batch. Price without purity is half a number, and a cheap vial that tested at 60% of label is not cheap. Run any certificate you hold through our free COA verify tool, and look up your compound and vendor in the public COA corpus before you trust the milligrams on the cap. The corpus is the point of the whole exercise: we publish the source price next to the reseller price so the markup shows up in dollars, and we publish the third-party lab result so you can tell whether the markup funded a test or a sticker.

The difference between us and an aggregator fits in one breath. They tell you which middleman is cheapest. We show you the source price and the lab test, and let you decide whether the middleman is worth it.

The grey market is not the villain here, and neither is convenience. Plenty of people will look at $0.78/mg versus three weeks from customs with no recourse and reasonably pay a reseller for speed, splits, and a tested batch. That is a fair trade made with open eyes. The unfair trade is the one made in the dark: 10x for a vial whose source price and source COA were public the whole time, dressed in a holographic label to look like the markup bought something. Everything we publish exists to move that trade into the light, where you can see both numbers and make the call yourself.

Research and education only. Not medical advice and not an endorsement of self-sourcing peptides, which are not quality-controlled medicines and carry real risk of under-dosing, contamination, and harm with no clinician in the loop. Source per-mg figures are in-stock medians computed from independent vendor pricing data, single-compound rows only, validated against the independently confirmed retatrutide figure of $0.78/mg. Reseller figures are the cheapest-reseller per-mg (DisclosedLabs) and the cross-vendor median (PeptideBase) captured directly with raw sources retained for fact-check. Supply-chain and markup claims are drawn from public reporting on the China-to-US relabel trade and are stated as patterns, not accusations against any named vendor. The two-possibilities framing of price aggregators is posed as an open question, not an allegation. If we have a figure wrong, the contact link is in the footer, and we correct the record.